Targeting IL-3Rα on tumor-derived endothelial cells blunts metastatic spread of triple-negative breast cancer via extracellular vesicle reprogramming

The lack of approved targeted therapies highlights the need for new treatments for triple-negative breast cancer (TNBC) patients. Interleukin-3 (IL-3) acts as an autocrine factor for tumor–endothelial cells (TEC), and exerts pro-angiogenic paracrine action via extracellular vesicles (EVs). IL-3Rα bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopatina, Tatiana, Grange, Cristina, Cavallari, Claudia, Navarro-Tableros, Victor, Lombardo, Giusy, Rosso, Arturo, Cedrino, Massimo, Pomatto, Margherita Alba Carlotta, Koni, Malvina, Veneziano, Francesca, Castellano, Isabella, Camussi, Giovanni, Brizzi, Maria Felice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548009/
https://www.ncbi.nlm.nih.gov/pubmed/33040091
http://dx.doi.org/10.1038/s41389-020-00274-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548009/
https://www.ncbi.nlm.nih.gov/pubmed/33040091
http://dx.doi.org/10.1038/s41389-020-00274-y

Ejemplares similares